Market Cap 1.01M
Revenue (ttm) 4.86M
Net Income (ttm) -2.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -48.15%
Debt to Equity Ratio 0.00
Volume 51,467
Avg Vol 2,648,772
Day's Range N/A - N/A
Shares Out 2.41M
Stochastic %K 17%
Beta 0.56
Analysts Strong Buy
Price Target $12.00

Company Profile

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 214 974 8921
Fax: 530 756 7027
Address:
5956 Sherry Lane, Suite 2000, Dallas, United States
stoxtr
stoxtr Aug. 18 at 11:58 PM
$ABVEF $RKDA RKDA theme already destroyed by so called private placements! Now ABVE started private placements?? Where are we are going? Any details about the price at which the private placement has been done??
1 · Reply
ArbitrageMoto
ArbitrageMoto Aug. 18 at 7:41 PM
$RKDA all past CEOs need to be jailed like Elisabeth Holmes.
0 · Reply
ArbitrageMoto
ArbitrageMoto Aug. 18 at 7:41 PM
$RKDA 20:1 split coming. I won’t be surprise if it is 40:1. lol
0 · Reply
epistox
epistox Aug. 17 at 5:57 PM
$RKDA this has no intrinsic value...all theme is destroyed by that proposed issue of 12 million shares !!!
0 · Reply
epistox
epistox Aug. 14 at 12:13 PM
$RKDA it can be bought only in the range of .05 to .10...otherwise too expensive
0 · Reply
Danjaftw
Danjaftw Aug. 12 at 8:09 PM
$RKDA hello!
0 · Reply
beatrix19
beatrix19 Aug. 6 at 4:05 PM
$RKDA when 1$
1 · Reply
epistox
epistox Aug. 6 at 10:59 AM
$RKDA remove your blindness...half of those shares can be issued without shareholders approval immediatelyat 0.91...!!!!
1 · Reply
Jmoney914
Jmoney914 Aug. 6 at 10:51 AM
$RKDA the 10 mil shares at .91 cannot be issued prior to shareholder approval. Annual meeting is on 9/10.
0 · Reply
epistox
epistox Aug. 6 at 2:51 AM
$RKDA what premium??? nobody buys these pennies for a 20% return....that private placement has totally ruined all the story about this stock...above 0.91, there will be 10million more shares available here for sell, very despicable situation
0 · Reply
Latest News on RKDA
Arcadia Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 6 days ago

Arcadia Biosciences Quarterly report: Q2 2026


Arcadia Biosciences Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 6 days ago

Arcadia Biosciences Earnings release: Q2 2026


Arcadia Biosciences Proxy statement: Proxy filing

Aug 10, 2026, 8:00 AM EDT - 10 days ago

Arcadia Biosciences Proxy statement: Proxy filing


Arcadia Biosciences Proxy statement: Proxy filing

Jul 31, 2026, 8:00 AM EDT - 20 days ago

Arcadia Biosciences Proxy statement: Proxy filing


Arcadia Biosciences Registration statement: Registration filing

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

Arcadia Biosciences Registration statement: Registration filing


Arcadia Biosciences Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Arcadia Biosciences Quarterly report: Q1 2026


Arcadia Biosciences Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Arcadia Biosciences Earnings release: Q1 2026


Arcadia Biosciences Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Arcadia Biosciences Annual report: Q4 2025


Arcadia Biosciences Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Arcadia Biosciences Earnings release: Q4 2025


Arcadia Biosciences Registration statement: Registration Filing

Jan 28, 2026, 7:00 AM EST - 7 months ago

Arcadia Biosciences Registration statement: Registration Filing


Arcadia Biosciences Proxy statement: Proxy Filing

Nov 19, 2025, 7:00 AM EST - 9 months ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Arcadia Biosciences Earnings release: Q3 2025


Arcadia Biosciences Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

Arcadia Biosciences Quarterly report: Q3 2025


Arcadia Biosciences Quarterly report: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Arcadia Biosciences Quarterly report: Q2 2025


Arcadia Biosciences Earnings release: Q2 2025

Aug 14, 2025, 9:30 AM EDT - 1 year ago

Arcadia Biosciences Earnings release: Q2 2025


Arcadia Biosciences Earnings Call Transcript: Q1 2025

May 8, 2025, 2:00 PM EDT - 1 year ago

Arcadia Biosciences Earnings Call Transcript: Q1 2025


Arcadia Biosciences Quarterly report: Q1 2025

May 8, 2025, 2:00 PM EDT - 1 year ago

Arcadia Biosciences Quarterly report: Q1 2025


Arcadia Biosciences Earnings release: Q1 2025

May 8, 2025, 2:00 PM EDT - 1 year ago

Arcadia Biosciences Earnings release: Q1 2025


Arcadia Biosciences Earnings Call Transcript: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

Arcadia Biosciences Earnings Call Transcript: Q4 2024


Arcadia Biosciences Annual report: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

Arcadia Biosciences Annual report: Q4 2024


Arcadia Biosciences Earnings release: Q4 2024

Mar 20, 2025, 4:30 PM EDT - 1 year ago

Arcadia Biosciences Earnings release: Q4 2024


Arcadia Biosciences Transcript: M&A Announcement

Dec 11, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Transcript: M&A Announcement


Arcadia Biosciences Press release: M&A Announcement

Dec 11, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Press release: M&A Announcement


Arcadia Biosciences Slides: M&A Announcement

Dec 11, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Slides: M&A Announcement


Arcadia Biosciences reports Q3 EPS ($1.18), consensus (81c)

2024-11-12T22:50:20.000Z - 1 year ago

Arcadia Biosciences reports Q3 EPS ($1.18), consensus (81c)


Arcadia Biosciences Earnings Call Transcript: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Earnings Call Transcript: Q3 2024


Arcadia Biosciences Quarterly report: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Quarterly report: Q3 2024


Arcadia Biosciences Earnings release: Q3 2024

Nov 12, 2024, 4:30 PM EST - 1 year ago

Arcadia Biosciences Earnings release: Q3 2024


Arcadia Biosciences Earnings Call Transcript: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings Call Transcript: Q2 2024


Arcadia Biosciences Quarterly report: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Quarterly report: Q2 2024


Arcadia Biosciences Earnings release: Q2 2024

Aug 13, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings release: Q2 2024


Arcadia Biosciences reports Q2 EPS 78cs vs 61c last year

2024-08-13T20:06:44.000Z - 2 years ago

Arcadia Biosciences reports Q2 EPS 78cs vs 61c last year


Arcadia Biosciences (RKDA) Announces Leadership Transition

Jul 9, 2024, 8:02 AM EDT - 2 years ago

Arcadia Biosciences (RKDA) Announces Leadership Transition


Arcadia Biosciences Transcript: Status Update

May 22, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Transcript: Status Update


Arcadia Biosciences Press release: Status Update

May 22, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Press release: Status Update


Arcadia Biosciences Proxy statement: Proxy Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Proxy statement: Proxy Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings Call Transcript: Q1 2024


Arcadia Biosciences Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Quarterly report: Q1 2024


Arcadia Biosciences Earnings release: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings release: Q1 2024


Arcadia Biosciences Earnings Call Transcript: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings Call Transcript: Q4 2023


Arcadia Biosciences Annual report: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Annual report: Q4 2023


Arcadia Biosciences Earnings release: Q4 2023

Mar 28, 2024, 4:30 PM EDT - 2 years ago

Arcadia Biosciences Earnings release: Q4 2023


Arcadia Biosciences Earnings Call Transcript: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

Arcadia Biosciences Earnings Call Transcript: Q3 2023


Arcadia Biosciences Quarterly report: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

Arcadia Biosciences Quarterly report: Q3 2023


Arcadia Biosciences Earnings release: Q3 2023

Nov 9, 2023, 4:30 PM EST - 3 years ago

Arcadia Biosciences Earnings release: Q3 2023


Arcadia Biosciences Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings Call Transcript: Q2 2023


Arcadia Biosciences Quarterly report: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Quarterly report: Q2 2023


Arcadia Biosciences Earnings release: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings release: Q2 2023


Arcadia Biosciences announces strategic review

2023-07-20T12:11:30.000Z - 3 years ago

Arcadia Biosciences announces strategic review


Arcadia Biosciences (RKDA) Announces Strategic Review

Jul 20, 2023, 8:02 AM EDT - 3 years ago

Arcadia Biosciences (RKDA) Announces Strategic Review


Arcadia Biosciences Earnings Call Transcript: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings Call Transcript: Q1 2023


Arcadia Biosciences Quarterly report: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Quarterly report: Q1 2023


Arcadia Biosciences Earnings release: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings release: Q1 2023


Arcadia Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Earnings Call Transcript: Q4 2022

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings Call Transcript: Q4 2022


Arcadia Biosciences Earnings release: Q4 2022

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Earnings release: Q4 2022


Arcadia Biosciences Annual report: Q4 2022

Mar 30, 2023, 4:30 PM EDT - 3 years ago

Arcadia Biosciences Annual report: Q4 2022


Arcadia Biosciences Proxy statement: Proxy Filing

Jan 6, 2023, 7:00 AM EST - 3 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences Proxy statement: Proxy Filing

Dec 23, 2022, 7:00 AM EST - 3 years ago

Arcadia Biosciences Proxy statement: Proxy Filing


Arcadia Biosciences (RKDA) Announces CFO Transition

Nov 30, 2022, 4:30 PM EST - 4 years ago

Arcadia Biosciences (RKDA) Announces CFO Transition


stoxtr
stoxtr Aug. 18 at 11:58 PM
$ABVEF $RKDA RKDA theme already destroyed by so called private placements! Now ABVE started private placements?? Where are we are going? Any details about the price at which the private placement has been done??
1 · Reply
ArbitrageMoto
ArbitrageMoto Aug. 18 at 7:41 PM
$RKDA all past CEOs need to be jailed like Elisabeth Holmes.
0 · Reply
ArbitrageMoto
ArbitrageMoto Aug. 18 at 7:41 PM
$RKDA 20:1 split coming. I won’t be surprise if it is 40:1. lol
0 · Reply
epistox
epistox Aug. 17 at 5:57 PM
$RKDA this has no intrinsic value...all theme is destroyed by that proposed issue of 12 million shares !!!
0 · Reply
epistox
epistox Aug. 14 at 12:13 PM
$RKDA it can be bought only in the range of .05 to .10...otherwise too expensive
0 · Reply
Danjaftw
Danjaftw Aug. 12 at 8:09 PM
$RKDA hello!
0 · Reply
beatrix19
beatrix19 Aug. 6 at 4:05 PM
$RKDA when 1$
1 · Reply
epistox
epistox Aug. 6 at 10:59 AM
$RKDA remove your blindness...half of those shares can be issued without shareholders approval immediatelyat 0.91...!!!!
1 · Reply
Jmoney914
Jmoney914 Aug. 6 at 10:51 AM
$RKDA the 10 mil shares at .91 cannot be issued prior to shareholder approval. Annual meeting is on 9/10.
0 · Reply
epistox
epistox Aug. 6 at 2:51 AM
$RKDA what premium??? nobody buys these pennies for a 20% return....that private placement has totally ruined all the story about this stock...above 0.91, there will be 10million more shares available here for sell, very despicable situation
0 · Reply
_Sensei_
_Sensei_ Aug. 5 at 4:50 PM
$RKDA adding dips, amazing chart + $4M private placement priced at a premium
0 · Reply
epistox
epistox Aug. 3 at 2:37 AM
$RKDA @Wohduhfok first learn some math and calculations, investing in RKDA at this price is equal to buying ABVE at 2.4$/share...... i have got some extra money , which i wanted to invest in ABVE to lower my average and currently we can do that just through RKDA....unfortunately nobody is ready to argue logically and answer my concerns....i m not left with any convincing argument to invest in RKDA...investing in RKDA at this price is equal to buying ABVE at 2.4$/share...
0 · Reply
Wokduhfok
Wokduhfok Aug. 2 at 6:42 PM
$ABVEF $RKDA You're conflating two separate corporate events. $RKDA’s capital raise has nothing to do with $ABVE’s operational health or asset value. The facts: 1. Why RKDA Raised Capital: RKDA did that dilutive preferred offering (Series A-1/A-2) because Roosevelt Resources terminated their planned merger. When the deal fell through, RKDA had to raise emergency capital to secure its own cash runway. 2. No Impact on ABVE: RKDA’s short-term liquidity needs don't change the fundamental value of Above Food. RKDA holds ABVE shares as a legacy asset. A shareholder needing cash for separate operations has zero bearing on the business viability of the stock they hold. 3. The "Dead" Claim is Wrong: Saying ABVE is dead because RKDA had a merger fall through makes no sense. RKDA's balance sheet issues are isolated to RKDA.You're panicking over micro-cap raising capital because of a merger termination. Read the sec filing on the Roosevelt termination before you go spouting conspiracy.
1 · Reply
cky1919
cky1919 Aug. 2 at 3:54 PM
0 · Reply
epistox
epistox Aug. 2 at 10:19 AM
$ABVEF $RKDA @Tim442 serious question marks are present..... that say that almost certainly, the appeal is going to be rejected....and company will have to be relisted like a new one later on with r/s and $4/share price....
0 · Reply
epistox
epistox Aug. 2 at 10:05 AM
$ABVEF $RKDA the biggest question mark has been created by RKDA actions (unless it has been done deliberately for insiders)....RKDA recently raised capital at 1.03$/share (around 3.8 million shares) with Extra Facility to same investors (at $0.91/share, around 7.7 million more shares) via two separate tranches of preferred investment options (Series A-1 and Series A-2).....that is a big question mark...if we assume a big prospect in ABVE , then these 'so called investors' will be free to sell around 12 million shares (paying first just around 0.91/share)......that demands a class action suit....or second scenario, ABVE is dead and we are doomed!!!
0 · Reply
B2iDigital
B2iDigital Jul. 27 at 9:32 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 6:25 PM
Genvor, Inc. (OTCQB: $GNVR), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
B2iDigital
B2iDigital Jul. 27 at 2:59 PM
Genvor, Inc. (OTCQB: $GNVR ), a biotechnology company harnessing AI to generate novel peptides, said its proprietary antimicrobial peptides are being evaluated for their potential to address microbial challenges in sugar beet production, under the USDA Agricultural Research Service (ARS) Sustainable Sugar Beet Research Initiative. Genvor is a @B2iDigital Featured Company. See the company's profile at https://b2idigital.com/genvor-incorporated-1 As a collaborator, the company is contributing its antimicrobial peptides for evaluation against key sugar beet microbial targets: • USDA-ARS researchers will evaluate whether Genvor's antimicrobial peptides can inhibit key microbes involved in sugar beet root rot and in downstream sugar extraction • The work may generate data to inform future peptide-based crop protection strategies "Our work with collaborators has consistently demonstrated how much peptide science can contribute to agriculture," said Dr. Jesse Jaynes, Co-Founder of Genvor and the founding scientist behind the company's core peptide technologies. "Extending that collaboration into sugar beet lets us apply our peptides to a new set of microbial targets and continue advancing the design work that makes these tools more effective." Read the full release: https://genvor.com/press-releases/post?storyId=6174274901791168 Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Learn more at https://www.genvor.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted GNVR stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EVGN $PTN $RKDA $DYAI
1 · Reply
RKDATopRetail
RKDATopRetail Jul. 22 at 5:10 PM
$RKDA Excited New Shareholder in Arcadia Biosciences (RKDA) Dear RKDA Community, I am pleased to announce that I have recently become a new shareholder of Arcadia Biosciences Inc. ($RKDA). I happily hold and approximately 0.15% of the company’s outstanding shares. I have been following the developments at Arcadia Biosciences with great interest and believe in the long-term potential of the company. Despite the current market volatility, I remain optimistic about its future prospects. I look forward to engaging with the community, sharing insights, and supporting the company’s journey. Let’s build value together! Best regards, A New RKDA Shareholder
0 · Reply
MaverickRazz
MaverickRazz Jul. 21 at 3:21 PM
$RKDA up ⬆️ soon
0 · Reply
Fullpockets247
Fullpockets247 Jul. 15 at 8:04 PM
$RKDA let’s see how this does overnight
0 · Reply